4.3 Article Proceedings Paper

Imperfect gold standards for biomarker evaluation

Journal

CLINICAL TRIALS
Volume 10, Issue 5, Pages 696-700

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/1740774513497540

Keywords

-

Funding

  1. NCATS NIH HHS [8UL1TR000170-05] Funding Source: Medline
  2. NCI NIH HHS [R01 CA075971, R01CA075971] Funding Source: Medline
  3. NIA NIH HHS [P50 AG005134] Funding Source: Medline
  4. NIDDK NIH HHS [R01 DK072381, R33 DK074099, R33DK074099, K23 DK075941, K23DK075941] Funding Source: Medline
  5. NINDS NIH HHS [T32NS048005, T32 NS048005] Funding Source: Medline

Ask authors/readers for more resources

Background Serum creatinine has been used as the diagnostic test for acute kidney injury (AKI) for decades despite having imperfect sensitivity and specificity. Novel tubular injury biomarkers may revolutionize the diagnosis of AKI; however, even if a novel tubular injury biomarker is 100% sensitive and 100% specific, it may appear inaccurate when using serum creatinine as the gold standard. Conclusions In general, the apparent diagnostic performance of a biomarker depends not only on its ability to detect injury but also on disease prevalence and the sensitivity and specificity of the imperfect gold standard. Apparent errors in diagnosis using a new biomarker may be a reflection of errors in the imperfect gold standard itself rather than poor performance of the biomarker.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available